Determination of tezosentan, a parenteral endothelin receptor antagonist, in human plasma by liquid chromatography-tandem mass spectrometry.
An analytical method was developed for the quantification of tezosentan in human plasma obtained in clinical studies. The method was linear in the range 1 to 512 ng/ml. After liquid-liquid extraction, the samples were analyzed by reversed-phase HPLC with tandem mass spectrometry. The limit of quantification was 1 ng/ml and the extraction recovery was at least 88.2%. Intra- and inter-assay coefficients of variation were below 10%. Stability tests revealed that tezosentan is stable under the different conditions tested.
van Giersbergen
Paul L M
PL
Department of Clinical Pharmacology, Actelion Pharmaceuticals Ltd, Gewerbestrasse 18, 4123 Allschwil, Switzerland. paul.vangiersbergen@actelion.com
Wipfli
Peter
P
Dingemanse
Jasper
J
D002851:Chromatography, High Pressure Liquid / Q000379:methods*; D065128:Endothelin Receptor Antagonists; D006801:Humans; D013058:Mass Spectrometry / Q000379:methods*; D011725:Pyridines / Q000097:blood*; D012680:Sensitivity and Specificity; D013777:Tetrazoles / Q000097:blood*
D065128:Endothelin Receptor Antagonists; D011725:Pyridines; D013777:Tetrazoles; C120582:tezosentan